Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-1427 in Moderately to Severely Active Ulcerative Colitis
2023-508304-38-00Phase 2Authorised
- Sponsor
- Gilead Sciences
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 2, randomised, double-blind trial of emvistegrast in autoimmune colitis (3 arms), sponsored by Gilead Sciences. Primary endpoint: Clinical response at Week 12. Planned start Jul 2024; status: authorised.
02
Drugs
emvistegrast
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-508304-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508304-38-00.